Cargando…
Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the adult population. Current efforts are focused on better understanding the intricate pathophysiology of the disease to develop successful targeted therapies. Ibrutinib is emerging as an important agent in this new age of targete...
Autores principales: | Khan, Maliha, Gibbons, Jamie L, Ferrajoli, Alessandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384733/ https://www.ncbi.nlm.nih.gov/pubmed/28408842 http://dx.doi.org/10.2147/OTT.S98689 |
Ejemplares similares
-
Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021) -
BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
por: Falchi, Lorenzo, et al.
Publicado: (2016) -
Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia
por: Chavez, Julio C, et al.
Publicado: (2013) -
Chronic Lymphocytic Leukemia
por: Vaisitti, Tiziana, et al.
Publicado: (2020) -
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)